Liberty University NURS 751 Midterm Study Guide | Complete
Neurobiology & Differential Diagnosis Exam Notes | PMHNP
Exam Review | 2026. Rating - Sold - 200 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Psychiatric Mental Health Nurse Practitioner (PMHNP)
Description This midterm exam assesses advanced knowledge in neurobiology,
psychopharmacology, and differential diagnosis for PMHNP students. It covers
neurotransmitter systems, brain circuitry, genetic influences, diagnostic criteria,
and evidence-based treatment planning for major psychiatric disorders.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Integrate neurobiological principles to explain pathophysiology of psychiatric
disorders
2. Apply DSM-5-TR criteria to formulate differential diagnoses
3. Evaluate psychopharmacologic and non-pharmacologic interventions based on
neurobiology
4. Analyze complex clinical cases incorporating genetic, epigenetic, and
environmental factors
Accreditation This examination adheres to the rigorous standards of Liberty University and the
American Association of Colleges of Nursing (AACN) for graduate-level
PMHNP education.
Page 1
,1. A patient with treatment-resistant depression shows inadequate response to
multiple SSRIs and SNRIs. Neuroimaging reveals reduced hippocampal volume and
hyperactive default mode network. Which augmentation strategy is most directly
supported by this neurobiological profile?
A. Add aripiprazole to enhance prefrontal dopamine
B. Add ketamine to promote synaptogenesis in the hippocampus
C. Add buspirone to modulate 5-HT1A autoreceptors
D. Add bupropion to increase norepinephrine and dopamine
Answer: B. Add ketamine to promote synaptogenesis in the hippocampus
Ketamine rapidly increases synaptic connectivity in the hippocampus and reduces
default mode network hyperactivity. Aripiprazole targets dopamine but not directly
hippocampal volume. Buspirone and bupropion lack robust evidence for reversing
hippocampal atrophy.
2. Which of the following best explains why a patient with panic disorder may
experience symptom exacerbation when starting an SSRI, and how this guides initial
dosing?
A. SSRIs increase serotonin in the raphe nuclei, activating 5-HT2A receptors that initially
heighten anxiety; start at half the usual dose
B. SSRIs block norepinephrine reuptake, increasing sympathetic tone; start with a
beta-blocker
C. SSRIs potentiate GABAergic inhibition, causing sedation; start at bedtime
D. SSRIs inhibit CYP450 enzymes, raising drug levels; start with a very low dose and titrate
slowly
Answer: A. SSRIs increase serotonin in the raphe nuclei, activating 5-HT2A
receptors that initially heighten anxiety; start at half the usual dose
Initial SSRI therapy increases serotonin in the raphe, stimulating 5-HT2A receptors
and worsening anxiety before desensitization. Starting at a low dose minimizes this
effect. SSRIs do not block norepinephrine reuptake, and CYP450 inhibition is not the
primary mechanism for exacerbation.
Page 2
,3. A patient with schizophrenia has persistent negative symptoms despite adequate
antipsychotic therapy. Neurobiologically, this correlates with reduced activity in
which brain region and which neurotransmitter system?
A. Prefrontal cortex; dopamine D1 hypofunction
B. Striatum; dopamine D2 hyperfunction
C. Hippocampus; glutamate hyperfunction
D. Thalamus; GABA hypofunction
Answer: A. Prefrontal cortex; dopamine D1 hypofunction
Negative symptoms in schizophrenia are linked to hypofrontality and reduced
dopamine D1 receptor signaling in the prefrontal cortex. D2 hyperfunction in the
striatum relates to positive symptoms. Glutamate and GABA abnormalities are
secondary.
4. Which finding from the CATIE trial most directly challenges the notion that
second-generation antipsychotics are uniformly superior to first-generation agents
for overall effectiveness?
A. Olanzapine had the highest discontinuation rate due to metabolic side effects
B. Perphenazine, a first-generation agent, showed comparable time to all-cause
discontinuation
C. Clozapine was reserved for treatment-resistant patients and showed superior efficacy
D. Risperidone caused more extrapyramidal symptoms than haloperidol
Answer: B. Perphenazine, a first-generation agent, showed comparable time to
all-cause discontinuation
In CATIE, perphenazine (a first-generation antipsychotic) was not significantly
different from several second-generation agents in time to all-cause discontinuation,
suggesting comparable overall effectiveness. Olanzapine had lower discontinuation but
more metabolic effects. Clozapine was not part of the main comparison.
Page 3
, 5. A patient with bipolar I disorder experiences a depressive episode while on lithium
monotherapy. Which pharmacologic strategy is most consistent with current
evidence from systematic reviews?
A. Add lamotrigine for acute bipolar depression
B. Switch to valproate monotherapy
C. Add an SSRI such as fluoxetine
D. Augment with quetiapine at low dose
Answer: D. Augment with quetiapine at low dose
Quetiapine has strong evidence for acute bipolar depression. Lamotrigine is more
effective for prophylaxis than acute treatment. Valproate is less effective for depression.
SSRIs may increase risk of mood switching without robust efficacy.
6. A patient with generalized anxiety disorder and comorbid alcohol use disorder
reports poor response to sertraline. Which neurobiological consideration is most
relevant for choosing an alternative?
A. Alcohol enhances GABAergic inhibition, so a medication that also potentiates GABA
(e.g., pregabalin) may be beneficial
B. Alcohol withdrawal causes glutamate rebound, so an NMDA antagonist (e.g., memantine)
is indicated
C. Sertraline failure suggests dopamine dysfunction, so bupropion is preferred
D. Comorbid alcohol use disorder requires disulfiram before treating anxiety
Answer: A. Alcohol enhances GABAergic inhibition, so a medication that also
potentiates GABA (e.g., pregabalin) may be beneficial
Pregabalin increases GABA levels and has evidence for GAD, especially in patients
with alcohol use disorder. Memantine is not FDA-approved for GAD. Bupropion may
lower seizure threshold and is not first-line for GAD. Disulfiram does not treat anxiety.
Page 4
Neurobiology & Differential Diagnosis Exam Notes | PMHNP
Exam Review | 2026. Rating - Sold - 200 Questions and Answers
Already Graded A+ Premium Exam Tested And Verified
Subject Area Psychiatric Mental Health Nurse Practitioner (PMHNP)
Description This midterm exam assesses advanced knowledge in neurobiology,
psychopharmacology, and differential diagnosis for PMHNP students. It covers
neurotransmitter systems, brain circuitry, genetic influences, diagnostic criteria,
and evidence-based treatment planning for major psychiatric disorders.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Integrate neurobiological principles to explain pathophysiology of psychiatric
disorders
2. Apply DSM-5-TR criteria to formulate differential diagnoses
3. Evaluate psychopharmacologic and non-pharmacologic interventions based on
neurobiology
4. Analyze complex clinical cases incorporating genetic, epigenetic, and
environmental factors
Accreditation This examination adheres to the rigorous standards of Liberty University and the
American Association of Colleges of Nursing (AACN) for graduate-level
PMHNP education.
Page 1
,1. A patient with treatment-resistant depression shows inadequate response to
multiple SSRIs and SNRIs. Neuroimaging reveals reduced hippocampal volume and
hyperactive default mode network. Which augmentation strategy is most directly
supported by this neurobiological profile?
A. Add aripiprazole to enhance prefrontal dopamine
B. Add ketamine to promote synaptogenesis in the hippocampus
C. Add buspirone to modulate 5-HT1A autoreceptors
D. Add bupropion to increase norepinephrine and dopamine
Answer: B. Add ketamine to promote synaptogenesis in the hippocampus
Ketamine rapidly increases synaptic connectivity in the hippocampus and reduces
default mode network hyperactivity. Aripiprazole targets dopamine but not directly
hippocampal volume. Buspirone and bupropion lack robust evidence for reversing
hippocampal atrophy.
2. Which of the following best explains why a patient with panic disorder may
experience symptom exacerbation when starting an SSRI, and how this guides initial
dosing?
A. SSRIs increase serotonin in the raphe nuclei, activating 5-HT2A receptors that initially
heighten anxiety; start at half the usual dose
B. SSRIs block norepinephrine reuptake, increasing sympathetic tone; start with a
beta-blocker
C. SSRIs potentiate GABAergic inhibition, causing sedation; start at bedtime
D. SSRIs inhibit CYP450 enzymes, raising drug levels; start with a very low dose and titrate
slowly
Answer: A. SSRIs increase serotonin in the raphe nuclei, activating 5-HT2A
receptors that initially heighten anxiety; start at half the usual dose
Initial SSRI therapy increases serotonin in the raphe, stimulating 5-HT2A receptors
and worsening anxiety before desensitization. Starting at a low dose minimizes this
effect. SSRIs do not block norepinephrine reuptake, and CYP450 inhibition is not the
primary mechanism for exacerbation.
Page 2
,3. A patient with schizophrenia has persistent negative symptoms despite adequate
antipsychotic therapy. Neurobiologically, this correlates with reduced activity in
which brain region and which neurotransmitter system?
A. Prefrontal cortex; dopamine D1 hypofunction
B. Striatum; dopamine D2 hyperfunction
C. Hippocampus; glutamate hyperfunction
D. Thalamus; GABA hypofunction
Answer: A. Prefrontal cortex; dopamine D1 hypofunction
Negative symptoms in schizophrenia are linked to hypofrontality and reduced
dopamine D1 receptor signaling in the prefrontal cortex. D2 hyperfunction in the
striatum relates to positive symptoms. Glutamate and GABA abnormalities are
secondary.
4. Which finding from the CATIE trial most directly challenges the notion that
second-generation antipsychotics are uniformly superior to first-generation agents
for overall effectiveness?
A. Olanzapine had the highest discontinuation rate due to metabolic side effects
B. Perphenazine, a first-generation agent, showed comparable time to all-cause
discontinuation
C. Clozapine was reserved for treatment-resistant patients and showed superior efficacy
D. Risperidone caused more extrapyramidal symptoms than haloperidol
Answer: B. Perphenazine, a first-generation agent, showed comparable time to
all-cause discontinuation
In CATIE, perphenazine (a first-generation antipsychotic) was not significantly
different from several second-generation agents in time to all-cause discontinuation,
suggesting comparable overall effectiveness. Olanzapine had lower discontinuation but
more metabolic effects. Clozapine was not part of the main comparison.
Page 3
, 5. A patient with bipolar I disorder experiences a depressive episode while on lithium
monotherapy. Which pharmacologic strategy is most consistent with current
evidence from systematic reviews?
A. Add lamotrigine for acute bipolar depression
B. Switch to valproate monotherapy
C. Add an SSRI such as fluoxetine
D. Augment with quetiapine at low dose
Answer: D. Augment with quetiapine at low dose
Quetiapine has strong evidence for acute bipolar depression. Lamotrigine is more
effective for prophylaxis than acute treatment. Valproate is less effective for depression.
SSRIs may increase risk of mood switching without robust efficacy.
6. A patient with generalized anxiety disorder and comorbid alcohol use disorder
reports poor response to sertraline. Which neurobiological consideration is most
relevant for choosing an alternative?
A. Alcohol enhances GABAergic inhibition, so a medication that also potentiates GABA
(e.g., pregabalin) may be beneficial
B. Alcohol withdrawal causes glutamate rebound, so an NMDA antagonist (e.g., memantine)
is indicated
C. Sertraline failure suggests dopamine dysfunction, so bupropion is preferred
D. Comorbid alcohol use disorder requires disulfiram before treating anxiety
Answer: A. Alcohol enhances GABAergic inhibition, so a medication that also
potentiates GABA (e.g., pregabalin) may be beneficial
Pregabalin increases GABA levels and has evidence for GAD, especially in patients
with alcohol use disorder. Memantine is not FDA-approved for GAD. Bupropion may
lower seizure threshold and is not first-line for GAD. Disulfiram does not treat anxiety.
Page 4
